2026-07-14T12:04:35-04:00 2025-12-31 824632985 DJK CPA APAC 72650 FRED WARING DR STE 203 PALM DESERT CA 922605009 990 2025-01-01 270339401 BEBPA INC BEBP 9516591957 3913 NW PHINNEY BAY DR BREMERTON WA 98312 CATHERINE PRITCHETT VP OF OPERATIONS 9516591957 2026-06-10 true JEFF GIGNAC CPA P02026828 7603409200 2026-06-10 2025 2025-03-06 01:10:19Z CATHERINE PRITCHETT 3913 NW PHINNEY BAY DR BRENERTON WA 98312 955916 false X WWW.BEBPA.ORG X 2009 CA BEPBA PROVIDES AN INTERNATIONAL FORUM FOR THE PRESENTATION AND DISCUSSION OF SCIENTIFIC ISSUES AND PROBLEMS ENCOUNTERED IN THE BIOPHARMACEUTICAL COMMUNITY. THE AIM OF THIS OPEN DISCUSSION IS TO PROMOTE DEVELOPMENT OF INNOVATIVE APPROACHES AND SOLUTION THUS FACILITATING SAFER AND FASTER BIOPHARMACEUTICAL PRODUCT DEVELOPMENT. 10 8 4 23 0 0 985221 920386 23234 35530 0 1008455 955916 0 0 433104 482534 0 0 445841 388848 878945 871382 129510 84534 1239787 1321887 11434 11434 1228353 1310453 X BEPBA PROVIDES AN INTERNATIONAL FORUM FOR THE PRESENTATION AND DISCUSSION OF SCIENTIFIC ISSUES AND PROBLEMS ENCOUNTERED IN THE BIOPHARMACEUTICAL COMMUNITY. THE AIM OF THIS OPEN DISCUSSION IS TO PROMOTE DEVELOPMENT OF INNOVATIVE APPROACHES AND SOLUTION THUS FACILITATING SAFER AND FASTER BIOPHARMACEUTICAL PRODUCT DEVELOPMENT. false false 349898 ESTABLISHING, REVIEWING AND GOVERNING RECURRENT SCIENTIFIC CONFERENCES. 93590 ESTABLISHING, REVIEWING AND GOVERNING RECURRENT SCIENTIFIC CONFERENCES. 93590 443488 true false false false false false false false false false false false false false true false false false false false true false false false false false false false false false false false false false false false false false false false false false false false false false false true 8 0 4 false false false false false false false false false X 10 8 false false false false false false false true true false false false true true true true true true true false CA X DJK CPA APAC 7603409200 44550 VILLAGE COURT 103 PALM DESERT CA 92260 CATHERINE PRITCHETT VP OF OPERAT 40.00 X X 107115 0 0 LAUREEN LITTLE PRESIDENT/DI 30.00 X X 87806 0 0 ANASTASIA KOZOREZOVA SECRETARY 40.00 X 76972 0 0 SUE CHARLTON DIRECTOR X 0 0 0 KEVIN VAN COTT DIRECTOR X 0 0 0 SIAN ESTDALE DIRECTOR X 0 0 0 MARIE GOTTAR-GUILLIER DIRECTOR X 0 0 0 BASSAM HALLIS PHD DIRECTOR X 0 0 0 PERCEVAL SONDAG DIRECTOR X 0 0 0 ANTON STETSENKO DIRECTOR X 0 0 0 HANS-JOACHIM WALLNY DIRECTOR X 0 0 0 271893 1 false false false EU BIOASSAY 402626 402626 HCP 222636 222636 US BIOASSAY 220534 220534 SPECIAL TOPIC CONFERENCES 74590 74590 920386 35530 35530 955916 955916 X 482534 93590 388944 350191 349898 293 4210 4210 31737 31737 2710 2710 871382 443488 427894 0 53441 105198 1180269 1215792 897 897 5180 1239787 1321887 11434 11434 11434 11434 X 1228353 1310453 1228353 1310453 1239787 1321887 84534 -2434 X false false X 458399 541584 737062 1008455 955916 3701416 458399 541584 737062 1008455 955916 3701416 3701416 458399 541584 737062 1008455 955916 3701416 1.00000 1.00000 0.00000 0.00000 X GRANTS PAYABLE 11396 CREDIT CARDS 38 11434 false EUROPE PROGRAM SERVICES CONFERENCE false false false false false false SCHEDULE F, PAGE 1, PART I, LINE 3 EUROPE 0 0 FORM 990 - ORGANIZATION'S MISSION BEPBA PROVIDES AN INTERNATIONAL FORUM FOR THE PRESENTATION AND DISCUSSION OF SCIENTIFIC ISSUES AND PROBLEMS ENCOUNTERED IN THE BIOPHARMACEUTICAL COMMUNITY. THE AIM OF THIS OPEN DISCUSSION IS TO PROMOTE DEVELOPMENT OF INNOVATIVE APPROACHES AND SOLUTION THUS FACILITATING SAFER AND FASTER BIOPHARMACEUTICAL PRODUCT DEVELOPMENT. FORM 990, PAGE 2, PART III, LINE 4D ESTABLISHING, REVIEWING AND GOVERNING RECURRENT SCIENTIFIC CONFERENCES. FORM 990, PAGE 6, PART VI, LINE 11B NO REVIEW WAS OR WILL BE CONDUCTED. FORM 990, PAGE 6, PART VI, LINE 12C ANNUALLY, WITHIN 30 DAYS OF ELECTION TO THE BOD EACH DIRECTOR SHALL COMPLETE AND FILE A QUESTIONNAIRE WITH THE SECRETARY WHICH DISCLOSES: A. ANY COMPENSATED SERVICES BY DIRECTOR OR CLOSE RELATIVE TO THE CORPORATION. B. ANY SUCH SERVICES CONTEMPLATED FOR THE UPCOMING YEAR; AND C. ANY SUCH SERVICES RENDERERED OR CONTEMPLATED BY A FIRM OR BUSINESS WITH WHICH THE DIRECTOR OR CLOSE RELATIVE IS ASSOCIATED. AFTER DISCLOSURE OF THE FINANCIAL INTEREST OR MATERIAL FACTS THE INTERESTED PERSON WILL LEAVE THE MEETING AND A DETERMINATION OF A CONFLICT OF INTEREST IS VOTED ON. IF IT IS DETERMINED THERE IS A VIOLATION THE COMMITTEE WILL NOTIFY THE PERSON AND GIVE THEM AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE AND AFTER HEARING THIS AND MAKING FURTHER INVESTIGATION IF WARRANTED WILL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. ANY MEMBER OF THE GOVERNING BOARD WHO RECEIVES DIRECTLY OR INDIRECTLY ANY COMPENSATION IS PRECLUDED FROM VOTING ON MATTERS PERTAINING TO THAT COMPENSATION. EACH DIRECTOR, PRINCIPAL OFFICER AND MEMBER OF A COMMITTEE WITH GOVERNING BOARD DELEGATED POWERS SHALL ANNUALLY SIGN A STATEMENT WHICH AFFIRMS SUCH PERSON RECEIVED A COPY OF THE CONFLICT OF INTEREST POLICY, READ AND UNDERSTANDS THE POLICY, AGREES TO COMPLY WITH THE POLICY AND UNDERSTANDS THE RULES AND LIMITATIONS IMPOSED UPON THE ORGANIZATION AS A CHARITABLE ORGANIZATION TO MAINTAIN ITS FEDERAL TAX EXEMPTION. PERIODIC REVEIWS WILL BE MADE TO ENSURE THE ABOVE AND OUTSIDE EXPERTS MAY BE USED. FORM 990, PAGE 6, PART VI, LINE 15A PERIODIC REVIEWS ARE MADE TO DETERMINE IF THE COMPENSATION ARRANGEMENTS AND BENEFITS ARE REASONABLE AND IN LINE WITH INDUSTRY STANDARDS. FORM 990, PAGE 6, PART VI, LINE 15B PERIODIC REVIEWS ARE MADE TO DETERMINE WHETHER COMPENSATION ARRANGEMENTS AND BENEFITS ARE REASONABLE AND IN LINE WITH INDUSTRY STANDARDS. FORM 990, PAGE 6, PART VI, LINE 19 THE GOVERNING DOCUMENTS ARE AVAILABLE FOR REVIEW ON THE WEBSITE. THE BROCHURES AND WRITTEN INFORMATION REGARDING THE ORGANIZATION DIRECT INTERESTED PARTIES TO THE WEBSITE. FORM 990, PART IX, LINE 11G TAXES 0 293 0 EUB MEETING EXPENSES 123,972 0 0 HCP MEETING EXPENSES 118,511 0 0 SPECIAL TOPIC WORKSHOPS 4,663 0 0 USB MEETING EXPENSES 94,469 0 0 ABA MEETING EXPENSES 2,326 0 0 CONFERENCE GO BAG 1,107 0 0 STAFF EDUCATION PROGRAMS 4,850 0 0 TOTAL 349,898 293 0